Nucleated Embryonic X-Linked Transgenesis (NEXT)
Published NC 1925
Written and Edited by: [redacted], [redacted], [redacted], Athena Research
Abstract

We, human beings, are the product of our genetic code. What we can become is an entirely different matter involving genetics. Using the murine model, the lab members at Titan Industries subsidiary group, Athena Research have been working on a hereditary gene therapy known as NEXT.
Many would be quick to dismiss our goals as contrived, but this paper is written not with the intent to prove them wrong, but simply to tell the truth. The truth that we can have accelerated healing, enhanced physical limitations, and control over powers that didn’t exist within the realm of human imagination before. And it all comes down to NEXT.

Introduction

Transgenic gene therapy, a field under much scrutiny, has been in and out of use to varying effects. The crux of the issue was determined to be not the technique, but the main component, meaning the gene itself. The Nir-34 gene is not one that would be found in the sequenced human genome. It only exists temporarily in embryonic cells, meaning that the NEXT procedure must be performed invitro.
However, it was discovered that even if the procedure succeeded, manifestation of the Nir gene occurred at time points between 3 days to 4 weeks after birth. The cause is still to be determined. However, the results have been tremendous in